Interferon gamma in the treatment of patients with moderate COVID-19

Introduction. Interferons are produced in response to the presence of pathogens cells and responsible for proper formation immune reaction. Preliminary data obtained studies properties recombinant interferon gamma (IFN-γ) that involved patients with community-acquired pneumonia (including bacterial), acute respiratory viral infection (ARVI), influenza new coronavirus have shown promising results.The purpose study was assess effect subcutaneous administration IFN-γ on changes vital signs duration hospital stay.Material methods. An open-label, randomized, low-interventional included moderate COVID-19 over 18 years age both sexes. 500,000 IU administered s/c, daily, once a day, during 5 days.Results. IFN-y addition complex therapy disease resulted more favorable stabilization signs, as well reduced length fever stay by 2 days what allows suggesting positive this substance recovery processes COVID-19. Special emphasis should be made fact who received IFN- γ experienced no progression failure required transfer intensive care unit.Discussion. This confirms earlier rate clinical infections. Presented results limited small number patients; further drug post-marketing is required.Conclusion. Progress treatment adding may reasonably expand range existing options infection.